Expert consensus on the clinical and pharmaceutical application of ivabradine
-
-
Key words:
- ivabradine /
- clinical application /
- pharmaceutical practice /
- expert consensus
-
-
[1] DiFrancesco D.The role of the funny current in pacemaker activity[J].Circ Res,2010,106(3):434-446.
[2] 国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2019,11(7):1-78.
[3] 伊伐布雷定中国说明书.核准日期:2017年9月12日.
[4] Pereira-Barretto AC.Cardiac and Hemodynamic Benefits:Mode of Action of Ivabradine in Heart Failure[J].Adv Ther,2015,32(10):906-919.
[5] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[6] Ponikowski P,Voors AA,Anker SD,et al.2016 ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology( ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,37(27):2129-2200.
[7] Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-e161.
[8] Swedberg K,Komajda M,B9hm M,et al.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376(9744):875-885.
[9] 胡大一,黄德嘉,袁祖贻,等.盐酸伊伐布雷定治疗中国慢性心力衰竭患者的有效性及安全性评价:SHIFT研究中国亚组数据分析[J].中华心血管病杂志,2017,45(3):190-197.
[10] Guzman M,Gomez R,Romero SP,et al.Prognosis of heart failure treated with digoxin or with ivabradine:A cohort study in the community[J].Int J Clin Pract,2018,72(11):e13217.
[11] Hidalgo FJ,Anguita M,Castillo JC,et al.Effect of early treatment with ivabradine combined with betablockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction(ETHIC-AHF):A randomised study[J].Int J Cardiol,2016,217:7-11.
[12] Saldarriaga CI,Gonzalez G,Navarrete S,et al.Effect of ivabradine in the vulnerable phase:results from de optimize Colombia project[J].Eur J Heart Fail,2017,19(S1):231.
[13] Othman K,Mostafa M,Yosef AE,et al.Safety and efficacy of off-label use of ivabradine in patients with acute heart failure[J].J Saudi Heart Assoc,2019,31(4):179-187.
[14] Greene SJ,Fonarow GC,Vaduganathan M,et al.The vulnerable phase after hospitalization for heart failure[J].Nat Rev Cardiol,2015,12(4):220-229.
[15] Komajda M,Tavazzi L,Swedberg K,et al.Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure:apost-hoc analysis of SHIFT[J].Eur J Heart Fail,2016,18(9):1182-1189.
[16] Raja DC,Kapoor A,Sinha A,et al.Heart rate manipulation in dilated cardiomyopathy:Assessing the role of Ivabradine[J].Indian Heart J,2018,70(2):246-251.
[17] Bagriy AE,Schukina EV,Samoilova OV,et al.Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective,open-label study[J].Adv Ther,2015,32(2):108-119.
[18] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[19] Knuuti J,Wijns W,Saraste A,et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020,41(3):407-477.
[20] Tardif JC,Ponikowski P,Kahan T,et al.Efficacy of the I(f)current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy:a4-month,randomized,placebo-controlled trial[J].Eur Heart J,2009,30(5):540-548.
[21] Fox K,Ford I,Steg PG,et al.Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction(BEAUTIFUL):a randomised,double-blind,placebo-controlled trial[J].Lancet,2008,372(9641):807-816.
[22] Fox K,Ford I,Steg PG,et al.Ivabradine in stable coronary artery disease without clinical heart failure[J].N Engl J Med,2014,371(12):1091-1099.
[23] Tardif JC,Ford I,Tendera M,et al.Efficacy of ivabradine,a new selective I(f)inhibitor,compared with atenolol in patients with chronic stable angina[J].Eur Heart J,2005,26(23):2529-2536.
[24] Zarifis J,Kallistratos M,Katsivas A,et al.Antianginal Efficacy of Ivabradine/Metoprolol Combination in Patients With Stable Angina[J].Clin Cardiol,2016,39(12):697-702.
[25] Koester R,Kaehler J,Ebelt H,et al.Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice[J].Clin Res Cardiol,2010,99(10):665-672.
[26] Werdan K,Ebelt H,Nuding S,et al.Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris:results from the ADDITIONS study[J].Clin Res Cardiol,2012,101(5):365-373.
[27] Glezer M,Vasyuk Y,Karpov Y.Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina(CONTROL-2Study)[J].Adv Ther,2018,35(3):341-352.
[28] Priti K,Ranwa BL,Gokhroo RK,et al.Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine"[J].Cardiovasc Ther,2017,35(4).
[29] Barillà F,Pannarale G,Torromeo C,et al.Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock:A Preliminary Randomized Prospective Study[J].Clin Drug Investig,2016,36(10):849-856.
[30] 张文颖,徐验,钟新波,等.伊伐布雷定早期应用对急性ST段抬高型心肌梗死患者左心室重构影响的探索性研究[J].中华心力衰竭和心肌病杂志,2020,04(2):92-97.
[31] Fasullo S,Cannizzaro S,Maringhini G,et al.Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function:preliminary findings[J].J Card Fail,2009,15(10):856-863.
[32] Gerbaud E,Montaudon M,Chasseriaud W,et al.Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction:A pilot study[J].Arch Cardiovasc Dis,2014,107(1):33-41.
[33] Brugada J,Katritsis DG,Arbelo E,et al.2019 ESCGuidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology( ESC)[J].Eur Heart J,2020,41(5):655-720.
[34] Page RL,Joglar JA,Caldwell MA,et al.2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J].Circulation,2016,133(14):e506-574.
[35] Cappato R,Castelvecchio S,Ricci C,et al.Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia:a prospective,randomized,placebo-controlled,double-blind,crossover evaluation[J].J Am Coll Cardiol,2012,60(15):1323-1329.
[36] Benezet-Mazuecos J,Rubio JM,FarréJ,et al.Longterm outcomes of ivabradine in inappropriate sinus tachycardia patients:appropriate efficacy or inappropriate patients[J].Pacing Clin Electrophysiol,2013,36(7):830-836.
[37] Mathew ST,Po SS,Thadani U.Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine:A pooled analysis of prospective studies[J].Heart Rhythm,2018,15(2):240-247.
[38] Banavalikar B,Shenthar J,Padmanabhan D,et al.Clinical and Electrophysiological Correlates of Incessant Ivabradine-Sensitive Atrial Tachycardia[J].Circ Arrhythm Electrophysiol,2019,12(8):e007387.
[39] Meles E,Carbone C,Maggiolini S,et al.A case of atrial tachycardia treated with ivabradine as bridge to ablation[J].J Cardiovasc Electrophysiol,2015,26(5):565-568.
[40] Bohora S,Lokhandwala Y,Parekh P,et al.Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine[J].J Cardiovasc Electrophysiol,2011,22(3):340-342.
[41] Gee ME,Watkins AK,Brown JN,et al.Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome:A Systematic Review[J].Am J Cardiovasc Drugs,2018,18(3):195-204.
[42] Ruzieh M,Sirianni N,Ammari Z,et al.Ivabradine in the treatment of postural tachycardia syndrome(POTS),a single center experience[J].Pacing Clin Electrophysiol,2017,40(11):1242-1245.
[43] Delle Donne G,Rosés Noguer F,Till J,et al.Ivabradine in Postural Orthostatic Tachycardia Syndrome:Preliminary Experience in Children[J].Am J Cardiovasc Drugs,2018,18(1):59-63.
[44] Doesch AO,Ammon K,Konstandin M,et al.Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients[J].Transplantation,2009,88(6):835-841.
[45] Doesch AO,Mueller S,Erbel C,et al.Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients:a longterm follow-up study[J].Drug Des Devel Ther,2013,7:1323-1328.
[46] Rivinius R,Helmschrott M,Rahm AK,et al.Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation[J].Clin Res Cardiol,2020.
[47] Lage-Gallé E,Romero-Rodríguez N,Nevado-Portero J,et al.Safety and effectiveness of ivabradine after cardiac transplantation[J].Transplant Proc,2010,42(8):3191-3192.
[48] Doesch AO,Celik S,Ehlermann P,et al.Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine[J].Transplantation,2007,84(8):988-996.
[49] Kurpesa M,Trzos E,Wierzbowska-Drabik K,et al.Ivabradine as a heart rate-lowering agent in a patient with end-stage renal failure after heart transplantation[J].Kardiol Pol,2010,68(6):684-686.
[50] Zwicker C,Becker M,Lepper W,et al.Cardiogenic shock due to tachycardiomyopathy after heart transplantation:successful treatment with ivabradine[J].Cardiology,2010,116(3):174-177.
[51] Zhang R,Bobylev D,Stiefel P,et al.Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated:results of 48-month study[J].Clin Res Cardiol,2012,101(8):631-636.
[52] 费舒扬,邢娜,裘毅刚,等.依伐布雷定在冠状动脉CT检查中应用的Meta分析[J].中国循证心血管医学杂志,2018,10(2):159-163.
[53] Celik O,Atasoy MM,Ertürk M,et al.Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography(CCTA)in patients receiving long-term calcium channel-blocker therapy[J].Acta Radiol,2014,55(6):676-681.
[54] Cademartiri F,Garot J,Tendera M,et al.Intravenous ivabradine for control of heart rate during coronary CT angiography:A randomized,double-blind,placebocontrolled trial[J].J Cardiovasc Comput Tomogr,2015,9(4):286-294.
[55] Adile KK,Kapoor A,Jain SK,et al.Safety and efficacy of oral ivabradine as a heart rate-reducing agent in patients undergoing CT coronary angiography[J].Br JRadiol,2012,85(1016):e424-e428.
[56] Qiu S,Shi S,Ping H,et al.Efficacy of Ivabradine versus β-Blockers for Heart Rate Reduction during Computed Tomography Coronary Angiography:A MetaAnalysis of Randomized Controlled Trials[J].Cardiology,2016,135(3):133-140.
[57] Guler EC,Yam Y,Jia K,et al.Effectiveness of pointof-care oral ivabradine for cardiac computed tomography[J].J Cardiovasc Comput Tomogr,2020.
[58] 伊伐布雷定美国FDA说明书.核准日期:2019年4月.
[59] Ashley C,Currie A.The Renal Drug Handbook[M].3rd ed.UK:Radcliffe Publishing Ltd,2009:404-404.
[60] Internal data:CLINICAL PHARMACOLOGY ANDBIOPHARMACEUTICS REVIEW(S).Reference ID:3730050.
[61] The International Pharmacopoeia:Liquid preparations for oral use.2019.
[62] Kockova R,Svatunkova J,Novotny J,et al.Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo[J].Am J Physiol Heart Circ Physiol,2013,304(6):H895-902.
[63] Portolés A,Terleira A,Calvo A,et al.Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers:an open-label,pharmacokinetic interaction clinical trial[J].J Clin Pharmacol,2006,46(10):1188-1194.
[64] Savelieva I,Camm J.Comparison of the effects of a selective If current inhibitor ivabradine and atenolol on the QT interval in patients with coronary artery disease[J].Heart Rhythm.2005,2(5):S145-S146.
[65] Frommeyer G,Weller J,Ellermann C,et al.Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome[J].Cardiovasc Toxicol,2019,19(2):129-135.
[66] Böhm M,Swedberg K,Komajda M,et al.Heart rate as a risk factor in chronic heart failure(SHIFT):the association between heart rate and outcomes in a randomised placebo-controlled trial[J].Lancet,2010,376(9744):886-894.
[67] European Medicines Agency:Committee for Medicinal Products for Human European Public Assessment Report(EPAR),Procoralan[online].https://www.ema.europa.eu/en/medicines/human/EPAR/procoralan.
[68] Iliuta L,Rac-Albu M.Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Cardiac Surgery[J].Cardiol Ther,2014,3(1-2):13-26.
[69] Tanboğa İH,Topçu S,Aksakal E,et al.The Risk of Atrial Fibrillation With Ivabradine Treatment:A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients[J].Clin Cardiol,2016,39(10):615-620.
-
计量
- 文章访问数: 370
- PDF下载数: 1193
- 施引文献: 0
下载: